Janssen seeks to block Celltrion's infliximab biosimilar
This article was originally published in Scrip
Executive Summary
Johnson & Johnson unit Janssen has filed a lawsuit seeking to block Celltrion from bringing its infliximab biosimilar, known as CTP13, to the US market.